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Background: Current German and European HIV guidelines recommend early evaluation of HCV treatment in all
HIV/HCV co-infected patients. However, there are still considerable barriers to initiate HCV therapy in everyday clinical
practice. This study evaluates baseline characteristics, “intention-to-treat” pattern and outcome of therapy of HCV/HIV
co-infected patients in direct comparison to HCV mono-infected patients in a “real-life” setting.
Methods: A large, single-center cohort of 172 unselected HCV patients seen at the Infectious Diseases Unit at the
University Medical Center Hamburg-Eppendorf from 2000–2011, 88 of whom HCV/HIV co-infected, was retrospectively
analyzed by chart review with special focus on demographic, clinical and virologic aspects as well as treatment outcome.
Results: Antiviral HCV combination therapy with PEG-interferon plus weight-adapted ribavirin was initiated in 88/172
(52%) patients of the entire cohort and in n = 36 (40%) of all HCV/HIV co-infected patients (group A) compared to n = 52
(61%) of the HCV mono-infected group (group B) (p = 0.006). There were no significant differences of the demographics
or severity of the liver disease between the two groups with the exception of slightly higher baseline viral loads in group
A. A sustained virologic response (SVR) was observed in 50% (n = 18) of all treated HIV/HCV co-infected patients versus
52% (n = 27) of all treated HCV mono-infected patients (p = 0.859). Genotype 1 was the most frequent genotype in both
groups (group A: n = 37, group B: n = 49) and the SVR rates for these patients were only slightly lower in the group of
co-infected patients (group A: n = 33%, group B: 40% p = 0.626). During the course of treatment HCV/HIV co-infected
patients received less ribavirin than mono-infected patients.
Conclusion: Overall, treatment was only initiated in half of the patients of the entire cohort and in an even smaller
proportion of HCV/HIV co-infected patients despite comparable outcome (SVR) and similar baseline characteristics. In the
light of newer treatment options, greater efforts to remove the barriers to treatment that still exist for a great proportion
of patients especially with HIV/HCV co-infection have to be undertaken.
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In HIV infected patients, liver-related disease has emerged
as a leading cause of morbidity and mortality. The preva-
lence of HCV/HIV co-infection in the HIV population
ranges from 10 to up to 50% [1,2]. On the other hand,
HIV co-infection may worsen the course of hepatitis C
infection, leading to faster progression of liver fibrosis* Correspondence: v.lunzen@uke.de
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unless otherwise stated.and cirrhosis, liver failure and development of hepato-
cellular carcinoma (HCC) [3]. Successful treatment of
chronic hepatitis C infection has been shown to stop fi-
brosis progression, prevent liver-associated diseases and
mortality of co-infected patients [4]. Therefore, current
German and European HIV guidelines recommend early
evaluation of all HIV/HCV co-infected patients for pos-
sible HCV treatment. In general, HCV genotype, liver
fibrosis, IL-28 haplotypes and quantitative HCV RNA
are important baseline predictors of SVR [5]. Demo-
graphic factors, histological parameters and treatmenttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Baseline characteristics of patient cohort







Patients, n 88 84 0.666
Age (y), mean (min./max.) 45 (26/64) 45 (20/72) 0.763
Sex, male/female (%) 66/22 (75/25) 52/32 (61/38) 0.092
Genotype, n (%)
1 37/88 (42) 49/84 (58) 0.033
2 3/88 (3) 9/84 (10) 0.060
3 25/88 (28) 15/84 (17) 0.102
4 2/88 (2) 5/84 (5) 0.222
Unknwon 21/88 (23) 6/84 (7) 0.003
Liver biopsy, n (%) 17/88 (19) 36/84 (42) 0.001
Fibrosis F3 – F4, n (%) 6/17 (35) 10/36 (27) 0.251
HCV RNA in IU/ml, mean 4 714 165 3 453 862 0.487
(min./max.) (3/9 × 107) (3/3 × 107)
HCV RNA > 800 000,
n (%)
66/88 (75) 32/84 (38) 0.001
HCV RNA < 800 000,
n (%)
22/88 (25) 52/84 (61) 0.001
Alanine transaminase
in U/l, mean (min./max.)
78 (3/526) 105 (15/610) 0.098
Start of heptitis C therapy,
n (%)
36 (40) 52 (61) 0.006
Liver biopsy, n (%) 10 (27) 27 (51) 0.024
(Fibrosis F3 – F4, n (%) 5 (13) 8 (29) 0.846
HCV RNA in IU/ml, mean 4 799 700 3 222 000 0.530
(min./max.) (800/9 × 107) (3/2 × 107)
HCV RNA> 800 000, n (%) 12 (33) 21 (40) 0.502
HCV RNA< 800 000, n (%) 24 (66) 31 (59) 0.502
Alanine transaminase
in U/l, mean (min./max.)
94 (29/526) 120 (18/610) 0.321
Duration of therapy in
weeks, mean (min./max.)




Peg-Interferon-alfa 2a, n (%) 27/36 (75) 41/52 (78) 0.672
Peg-Interferon-alfa 2b, n (%) 0/36 (0) 3/52 (5) 0.143
Non-peg-Interferon, n (%) 3/36 (8) 0/52 (0) 0.034
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but in general more than 50% of naïve mono-infected pa-
tients will achieve sustained virologic response (SVR) with
the current standard therapy (pegylated interferon plus
ribavirin) [6,7]. Two large registration trials have shown
lower sustained virologic response rates (SVR) for dual
therapy in HIV/HCV co-infected patients (~33%) com-
pared to mono-infected patients (47-54%) [8-12]. Higher
baseline HCV RNA levels and lower initial ribavirin doses
are quoted as possible explanation for the lower SVR seen
in co-infected patients [13]. Recent data suggest that
higher ribavirin doses are safe and well-tolerated in co-
infected patients [14]. Intensified, response guided dual
therapy can significantly increase the SVR in co-infected
patients [15]. However, less is known about the “real life”
treatment outcome of co-infected patients [15].
Great advances have been made with the introduction
of the protease inhibitors boceprevir, telaprevir and
simeprevir as well as the polymerase inhibitor sofosbuvir
that have also been approved for triple therapy in HIV/
HCV co-infection [16]. SVR rates of more than 80% have
been reported for the triple therapy of naïve patients re-
gardless of the HIV status [16-18].
Despite the unfavorable course of hepatitis C co-
infection in HIV positive patients, not all patients are re-
ferred to specialists for evaluation for HCV treatment
[19]. Furthermore, anti-HCV treatment is only initiated
in a subset of all patients for various reasons (e.g. sub-
stance abuse, social and psychiatric issues, fear of side
effects or drug-drug interactions especially in patients
on ART or anticipated low chance of SVR) even in spe-
cialized centers [20].
In this “real life” single center study we aimed to
summarize the experience and pitfalls of standard dual
HCV therapy over the last decade and analyze baseline
characteristics, treatment rates and patterns, and out-
come of therapy in a German cohort of HCV/HIV co-
infected patients. A similar and unselected group of
HCV mono-infected patients treated at the same center
was evaluated in direct comparison.
Methods
Study population and laboratory markers
88 HIV-seropositive and 84 HIV-seronegative, unpaired,
unmatched and unselected treatment-naïve patients with
chronic HCV infection were enrolled into this mono-
center, retrospective cohort study. All patients presented at
the Infectious Diseases Outpatient Clinic of the University
Medical Center Hamburg-Eppendorf, Germany in the time
period from 2000 – 2011 -before directly acting antivirals
(DAA’s) became readily available for the treatment of
HIV/HCV co-infection. The center is a tertiary care
referral center for HIV antiretroviral and HCV antiviral
therapy in Germany.Primary end point of the study was defined as sustained
viral response (SVR) by intention-to-treat analysis. Pa-
tient charts were analyzed regarding demographics, clin-
ical data (stage of HIV infection; stage of liver fibrosis;
therapy regimes and duration; reasons for treatment dis-
continuation; response to treatment; side effects) as well
as laboratory measures such as: HCV genotype; HCV
RNA at different time points; HIV RNA; CD4+ T cell
count and CD4+/CD8+ ratio at baseline. An assessment




























Figure 1 Mode of transmission of hepatitis C Infection.
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[21]. Hemoglobin levels of both groups were compared
at different time points to identify the correlation be-
tween treatment response and ribavirin dosage as well as
to understand whether co-infected patients have a higher
risk of developing anemia under HCV therapy [22].
Definitions
SVR was defined as an undetectable HCV RNA, 24 weeks
after end of treatment. A rapid virologic response (RVR),17
patie
88 HCV/HIV co-infected
started HCV therapy: 
36 patients (41%) 
no HCV treatment
52 patients (59%)
 on HAART:  
29 patients (81%) 
no HAART:  
7 patients (19%) 
SVR: 14 (48%) 
Discontinuation of therapy: 3  
Non-Responder: 4 
Breakthrough infection: 0 
Relapse: 6 
Unknown: 2 
SVR: 4 (57%) 
Discontinuation of therapy: 0  
Non-Responder: 1 
Breakthrough infection: 1 
Relapse: 1 
Figure 2 Enrollment, treatment allocation, and follow-up of study pardefined as an undetectable HCV RNA at week 4 of HCV
treatment, and early virologic response (EVR), defined as
an undetectable HCV-RNA or ≥2 log reduction of HCV-
RNA at week 12 of HCV treatment compared to the base-
line viral level. A virologic relapse was defined, if HCV
RNA decreased and remained below the limit of detection
(<50 IU/mL) during treatment but became detectable after
end of treatment. Virologic non-response was defined as
RNA level HCV RNA level above the limit of detection





started HCV therapy: 
52 patients (62%) 
no HCV treatment:  
32 patients (38%) 
SVR: 27 (52%) 
Discontinuation of therapy: 4  
Non-Responder: 3 














SVR all, n (%) 18/36 (50) 27/52 (52) 0.860
RVR, n (%) 9/36 (25) 17/52 (32) 0.440
EVR, n (%) 6/36 (17) 7/52 (13) 0.677
SVR GT 1, n (%) 5/15 (33) 11/27 (40) 0.626
SVR GT 2, n (%) 1/2 (50) 7/8 (87) 0.356
SVR GT 3, n (%) 9/14 (64) 7/12 (58) 0.756
SVR GT 4, n (%) 1/1 (100) 2/4 (50) 0.600
GT unknown, n (%) 2/36 (5) 0/52 (0) 0.809
SVR GT 1 + 4, n (%) 6/16 (37) 13/31 (41) 0.770
SVR GT 2 + 3, n (%) 10/16 (62) 14/20 (70) 0.636
Discontinuation of
therapy, n (%)
3/36 (12) 4/52 (7) 0.305
Breakthrough
infection, n (%)
1/36 (2) 0/52 0.410
Non-response, n (%) 5/36 (13) 3/52 (5) 0.130
Relapse, n (%) 7/36 (19) 9/52 (17) 0.482
Unknown, n (%) 2/36 (5) 9/52 (17) 0.105
SVR HAART treated
patients, n (%)
14/29 (48) n.a. n.a.
SVR non-HAART treated
patients, n (%)
4/7 (57) n.a. n.a.
SVR CD4 Nadir > 200/μl,
n (%)
9/18 (50) n.a. n.a.
SVR CD4 Nadir < 200/μl,
n (%)
9/18 (50) n.a. n.a.
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infection was defined according to the Center of Disease
Control (CDC) – classification, version 1993 [23].
Statistical analysis
Continuous variables are presented as the mean and
standard deviation and categorical parameters are shown
as the median and range. The x2 test and Mann-
Withney U test were used for analysis of categorical data
and of continuous data, respectively. A p value <0.05 was
considered to denote statistical significance. Multiple re-
gression analysis was performed to identify co-variables
that might have independently impacted the start of hepa-
titis C treatment.
Results
Here, we present treatment results of an unsponsored,
single-center study of a German cohort of HIV-negative
and HIV-infected patients with chronic HCV infection.
We analyzed a total number of 172 treatment-naïve
patients with chronic hepatitis C (genotype 1-4) infection.88 patients were HIV/HCV co-infected (group A), 84 pa-
tients were HCV mono-infected (group B) (Table 1).
There were no significant differences or relative shifts
of the demographics or genotype distributions.
In both groups rates of advanced fibrosis were low
(Fibrosis F3 – F4, n (%): 6 (35) versus 10 (27), p = 0.251),
however relative fewer liver biopsies were performed
in co-infected patients (p < 0.001) (Table 1). While the
mean viral load were similar in both groups, more pa-
tients with co-infection (n = 66, 75%) had high viral loads
(>800 000 IU/ml) than mono-infected patients (n = 32,
38%) (p < 0.001).
The reported mode of HCV transmission did not dif-
fer between groups, with IVDU being the greatest risk
factor (Figure 1). The probable mode of HCV transmis-
sion was not reported in more patients with mono-
infection than co-infection (38% versus 21%) (Table 1).
A total of 36 (40%) HCV/HIV co-infected patients
started anti-HCV therapy with standard combination
treatment regimen with either PEG-IFN alpha 2a or PEG-
IFN alpha 2b (weight adapted) for 48 weeks (genotype 1
and 4) or 24 weeks (genotypes 2 and 3) and weight-
adapted ribavirin doses of 800-1400 mg, respectively,
compared to n = 52 (61%) of mono-infected patients
(p = 0.006). Figure 2 summarizes the allocation of treat-
ment and follow-up.
The safety and tolerability of HCV treatment was gen-
erally good in both groups and there were no significant
differences in discontinuation of therapy. However, only
2/36 (5%) co-infected patients but 9/52 (17%) mono-
infected patients were lost to follow-up (p = 0.105).
Overall, SVR rates were comparable in both groups
(group A: 18/36 [50%]; group B: 27/52 [52%] (p = 0.859,
ns) (Table 2). There were also no differences detected
for any of the genotypes (GT) 1 through 4 (GT1: 5/15
[33%] versus 11/27 [40%], GT2 1/2 [50%] versus 7/8
[87%], GT3 9/14 [64%] versus 7/12 [58%], GT4 1/1
[100%] versus 2/4 [50%]). Notably, we neither observed
any significant differences of the early virologic response
rates, the relapse rates nor differences of the rate of side
effects in either group (Table 2). Of note, ART-naïve pa-
tients had similar SVR rates compared with those of
ART-treated patients (48% versus 57%, respectively). SVR
rates were identical for HIV-positive patients with nadir
CD4+ T cell counts of 200/μl and above compared to
those under 200/μl (Table 2). However, the numbers in
these subgroups were too low to conduct a valid statis-
tical analysis.
We did not find differences in the SVR rates over time
in patients treated in the first half in comparison to the
second half of the decade (data not shown).
The decrease of hemoglobin levels showed no significant
differences during the treatment course in both groups















































































Figure 3 Hemoglobin levels in g/dl of mono-infected (red) versus co-infected (blue) patients during the course of anti-HCV treatment.
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week versus 7567,2 mg/week; p = 0,027).
We also compared the demographic and clinical char-
acteristics of the mono and co-infected patients who re-
ceived treatment or were not treated (Tables 3 and 4).
Surprisingly, there were few differences between these
groups. Indeed, for the mono-infected patients, there was
not a single characteristic significantly different (Table 4).
In the group of co-infected patients, there were also few
differences between the patients who were treated versus
treatment naïve patients. In the univariate analysis ad-
vanced age (p = 0.04), high CD4+ T cell counts (absolute
p < 0.001, relative p = 0.001), a higher mean CD4+/CD8+
ratio (p = 0.001), lower HIV RNA levels (p = 0.015) and
thus a CDC classification A1 – A3 (p = 0.005), were asso-
ciated with the start of HCV treatment in the group of co-
infected patients (Table 3). However, multiple regression
analysis could not confirm any of those variables as inde-
pendent predictors for the initiation of HCV treatment in
both groups (data not shown).
80% (n = 29) of the co-infected patients receiving anti-
HCV treatment were on concurrent HAART. In con-
trast, none of the HCV untreated patients with HIV/
HCV co-infection were on concurrent HAART.
Discussion
Due to the enhanced risk of rapid progression of liver
disease, higher incidence of liver-related complications
and higher overall mortality, it is recommended that everyHIV/HCV co-infected patient should be evaluated for early
HCV treatment [4]. In the present study, we evaluated the
treatment decisions and clinical course of HCV/HIV co-
infected patients in a real-life treatment setting in a large
Northern German university-based cohort in direct com-
parison to an unselected group of unmatched mono-
infected patients treated by the same group of providers.
The first surprising finding is that overall treatment
was initiated in only half (88/172) of patients in the en-
tire cohort. Overall SVR was achieved in only 45/88
(51%) of these patients regardless of HIV co-infection
status. Our results are in agreement with the results of
studies from different parts of the world that show that
only a small proportion of the total HCV infected pa-
tient population is subjected to treatment and even less
are successfully treated [24]. Extrapolating this low num-
ber of total successful treatment initiation would have
enormous public health consequences [25-27].
This situation might be even worse given the more
rapid progression to end stage liver disease in patients
co-infected with HCV and HIV [1]. In our current co-
hort analysis the baseline characteristics of the mono-
and co-infected patients with HCV did not differ with
regard to stage and severity of liver disease with most
patients (group A n = 11; 65% versus group B n = 26; 72%)
displaying an early stage of disease (Fibrosis F1- F2). We
observed an overall SVR rate of 50% for all genotypes in
group A, which is comparable to SVR rates found in
randomized clinical trials of peg-INF and ribavirin in
Table 3 Baseline characteristics of HCV/HIV co-infected patients (HCV treated versus untreated)
Characteristics Group A: HCV/HIV co-infected patients,
treated (n = 36)
Group B: HCV/HIV co-infected patients,
untreated (n = 52)
p-values
Age, mean (min./max.) 47 (26/64) 45 (27/61) 0.040
Sex, male/female (%) 26/10 (72/28) 40/12 (77/23) 0.617
Genotype, n (%)
1 15 (42) 22 (42) 0.952
2 2 (6) 1 (2) 0.356
3 14 (39) 11 (21) 0.070
4 1 (2) 1 (2) 0.791
Unknown 4 (11) 17 (33) 0.020
Transmission of HCV, n (%)
IVDU 21 (58) 37 (71) 0.212
Transfusion 4 (11) 3 (6) 0.363
Needlestick injury 0 (0) 0 (0) n.a.
Tatoo 0 (0) 0 (0) n.a.
Sex 1 (3) 3 (6) 0.508
Unknown 10 (28) 9 (17) 0.241
CDC Classification, n (%)
A1 – A3 13 (36) 10 (19) 0.005
B1 – B3 9 (25) 7 (13) 0.168
C1 – C3 9 (25) 22(42) 0.059
Unknown 5 (13) 14 (26) 0.144
Liver biopsy, n (%) 7/36 (19) 5/52 (9) 0.186
Fibrosis F3 – F4, n (%) 5/7 (71) 1/5 (20) 0.029
HCV RNA in IU/ml, mean (min./max.) 4800 000 (800/9 × 107) 4 713 000 (3/6 × 107) 0.965
CD4 Count absolute, mean 553,1 396,73 0.001
CD4 Count > 200/μl, n (%) 25 (69) 21 (40) 0.007
CD4 Count < 200/μl, n 2 (3,5) 16 (30) 0.004
CD4 Count unknown, n (%) 7 (19) 15 (28) 0.317
CD4 Count relative, mean 27,9 22,2 0.001
CD4 Nadir in cells/μl, mean 208 194 0.689
CD4/CD8 Ratio, mean 0,67 0,49 0.001
HIV RNA in copy/ml, mean (minimum/maximum) 9 850 (3/16 × 104) 71 180 (3/12 × 105) 0.015
HIV Treatment, n (%) 29 (36) 0 (0) n.a.
NRTI, n (%) 20/29 (68) n.a. n.a.
NNRTI, n (%) 18/29 (62) n.a. n.a.
PI, n (%) 12/29 (41) n.a. n.a.
Intregrase Inh., n (%) 2/29 (6) n.a. n.a.
Entry Inh., n (%) 0 (0) n.a. n.a.
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However, the SVR rates in mono-infected patients (52%)
are slightly lower than those reported by a real-life cohort
study of mono-infected patients treated by gastroenterol-
ogists at the same institution in the same time span
(60,9%) [7]. The reasons for these differences are notclear, but we have to keep in mind that the ID clinic is at-
tending for international patients, who might have different
IL-28 haplotypes [7]. Also, it has to be noted that 9/84 of
the mono-infected patients were lost to follow-up.
The majority of patients received PEG interferon alpha
2a [29], three patients who were treated early in 2000
Table 4 Baseline characteristics of HCV mono-infected
patients (HCV treated versus untreated)









Age, mean (min./max.) 44 (22/65) 48 (20/72) 0.112
Sex, male/female (%) 34/18 (65/35) 17/15 (53/47) 0.264
Genotype, n (%)
1 27 (52) 22 (69) 0.129
2 8 (15) 1 (3) 0.078
3 12 (23) 3 (9) 0.111
4 4 (8) 1 (3) 0.390
Unknown 1 (2) 5 (16) 0.018
Transmission, n (%)
IVDU 28 (54) 14 (44) 0.369
Transfusion 2 (4) 4 (13) 0.135
Needlestick injury 2 (4) 1 (3) 0.863
Tatoo 2 (4) 0 (0) 0.262
Unknown 18 (35) 13 (41) 0.579







Liver biopsy, n (%) 27/52 (51) 9/32 (28) 0.032
Fibrosis F3 – F4,
n (%)
8/27 (29) 2/9 (22) 0.209
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direct-acting antiviral agents for hepatitis C genotype 1 in-
fection, such as boceprevir, telaprevir or simeprevir as well
as sofosbuvir [17,18,30,31], were not approved yet during
the analysed timeperiod.
Despite the satisfactory outcome and an acceptable
safety profile, hepatitis C therapy was overall only initi-
ated in half of the patients and even less frequently initi-
ated in HCV/HIV co-infected patients than in HCV
mono-infected patients (40% vs. 62%) (p = 0.006) despite
the lack of an absolute contraindication according to the
chart review in the majority of patients. Reiberger et al.
[24] previously also reported a considerable undertreat-
ment of chronic HCV infection in HCV/HIV co-infected
patients in a large multicenter study. While our retrospect-
ive mono-center study has many limitations that we are
aware of, it resembles a “real-life” setting allowing for an
evaluation of attitudes towards HCV treatment initiation
of the same infectious disease specialists in mono- versus
co-infected HCV patients. In our cohort HCV/HIV co-
infected patients received less frequently HCV treatment
compared to HCV mono-infected patients (p = 0.006) des-
pite being seen by the same specialized ID staff.
Further studies have to look into the reasons of treat-
ment deferral that could range from a potential contra-
indication to interferon treatment like depression, anemiaor other psychiatric illnesses, or possible objections against
treatment initiation because of suspected non adherence
and fears from the (co-infected) patient’s perspective, as
well as relative lower motivation to initiate treatment from
the provider perspective because of the fear of inducing
severe side effects or the (assumed) lower SVR rates in co-
infected patients [32]. Anecdotally, when confronted with
the results of the current study the treating ID specialists
were surprised by the high SVR rates seen in co-infected
patients -especially for the patients that were not on
HAART or with lower CD4+ T cell counts. In a follow up
study we plan to assess the provider and patient atti-
tudes towards HCV treatment in mono versus co-infected
patients by using standardized questionnaires to better
understand the barriers to treatment initiation.
Interestingly, in the group of untreated co-infected pa-
tients, all patients were HAART naïve. While deferral of
HAART treatment might be an indicator for problems
of adherence, it is still interesting that only a minority of
patients without concurrent HAART regimes received
HCV therapy and these patients showed excellent SVR
rates. Although guidelines generally recommend select-
ing patients for HCV treatment whose CD4+ T cell
count is high, no study of pegylated interferon plus riba-
virin has shown a significant association between CD4+
T cell count less than 350/μl at treatment initiation and
SVR to date [33,34]. However, the notion that HCV
treatment should only be performed in patients who are
on concurrent HAART is a very strong held belief and
might be a potential barrier for initiating HCV treatment
in HIV co-infection.
Despite comparable rates of development of anemia,
HCV/HIV co-infected patients received less ribavirin
than mono-infected patients during the course of treat-
ment (5764,3 mg/week versus 7567,2 mg/week; p = 0.027),
which may have contributed to the slightly lower SVR rates
in co-infected patients (50% versus 52%) [12,15].
It seems that treating physicians are more reluctant to
use appropriate weight adapted ribavirin dosages in
HCV patients co-infected with HIV. However, this treat-
ment pattern was not warranted since baseline hemoglobin
levels were comparable in both patient groups (group A:
14,6 g/dl versus group B: 14,5 g/dl) (Figure 3).
In our analysis, HCV treatment was only initiated in
half of the patients of the entire cohort at a University
based Infectious Diseases Center. Extrapolating these re-
sults for Germany, and taking into account the large
proportion of patients who statistically do not clear
HCV even after one or several courses of therapy is con-
sidered, a great number of HIV/HCV co-infected pa-
tients are still in need of efficient antiviral treatment
even after one decade of dual combination therapy.
Altogether greater efforts to understand and potentially
to remove the (provider as well as patient) barriers to
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portion of patients have to be undertaken [19,27].
Limitations to our study include the relatively small
number of patients, its retrospective design and an unequal
proportion of men and women in the study population.
For similar reasons we also abstained from performing
more elaborate statistical tests like multivariate analysis.
The lack of data on IL28B genotypes is another limita-
tion to the study. A recent study at our center in mono-
infected patients showed that our center attends only a
small number of patients with Asian or African origin
and approximately 20% of patients show a CC haplotype,
60% a C/T haplotype and 20% the T/T haplotype
(unpublished data). We would assume similar proportions
of Il28B haplotypes in our co-infected patients, however
cannot exclude the possibility of higher rates of patients
with a T/T haplotype as discussed above.
We conclude that overall HCV treatment was only
initiated in half of the cohort and even in a smaller
proportion of HCV/HIV co-infected patients despite
satisfactory outcome and similar baseline characteristics.
In the light of newer treatment options [17,18,30,31],
greater efforts to understand the barriers to treatment that
still exist for a great proportion of patients have to be
undertaken especially in patients co-infected with both vi-
ruses. Additionally, further efforts have to be undertaken
to implement the national and international HIV and
HCV guidelines to real life practice. Larger prospective
studies are needed to confirm our findings in view of
newer treatment option including directly acting antivirals
(DAA) for HCV infection.
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